The SESAR investigator-initiated trial completes patient enrollment
Sedana Medical AB (publ) today announces that the enrollment of the planned 700 patients in the SESAR trial has been completed. The trial Sevoflurane for Sedation in Acute Respiratory Distress Syndrome: A Multicenter Prospective Randomized Trial (SESAR) is an investigator-initiated trial (IIT) that is supported in part by Sedana Medical and by the French Ministry of Health.The SESAR trial, comparing sevoflurane via the Sedaconda ACD with intravenous propofol for up to 7 days is led by professor Matthieu Jabaudon and his team from Clermont Ferrand, France. The patient population consists of